GlassScriptPhysician profile
Susan S Laubach
NPI 1366656209
$86,117.48
in general payments reported to CMS, 2019-2025
28 companies · $24K in 2025
The $24K reported for 2025 was more than what 93% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $806 · 2020: $143 · 2021: $423 · 2022: $3,133 · 2023: $4,245 · 2024: $54K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $46K · Consulting Fee: $19K · Travel and Lodging: $12K · Food and Beverage: $4,323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $45,980.00 |
| Consulting Fee | $19,156.25 |
| Travel and Lodging | $12,153.23 |
| Food and Beverage | $4,322.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $55,500.18 | 2019-2025 | Xolair |
| Kaleo, INC. | $18,868.93 | 2019-2024 | Auvi-Q |
| Novartis Pharmaceuticals Corporation | $3,527.61 | 2022-2025 | Xolair |
| Greer Laboratories, INC. | $2,345.19 | 2025 | Palforzia |
| Aimmune Therapeutics, INC. | $2,012.50 | 2022 | |
| Glaxosmithkline, LLC. | $702.52 | 2022-2025 | Trelegy Ellipta, Nucala |
| Regeneron Healthcare Solutions, INC. | $395.90 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $392.21 | 2020-2025 | Cuvitru, Hyqvia, Takhzyro |
| Genzyme Corporation | $316.30 | 2022-2024 | |
| Grifols USA, LLC | $288.92 | 2019-2024 | Xembify |
| Genentech, INC. | $276.60 | 2022-2024 | Xolair |
| Csl Behring | $228.10 | 2019-2025 | Hizentra |
| Ars Pharmaceuticals Operations, INC. | $216.41 | 2025 | Neffy |
| Pfizer INC. | $199.47 | 2019-2023 | |
| Optinose US, INC. | $134.91 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $127.24 | 2019 | |
| Sobi, INC | $101.56 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $99.51 | 2022 | |
| Alk-Abello, INC | $74.46 | 2025 | Odactra |
| Pharming Healthcare, INC. | $63.06 | 2021-2022 | |
| Hospira, INC. | $55.17 | 2022-2023 | |
| Bio Products Laboratory USA, INC. | $52.86 | 2019 | |
| Verona Pharma, INC. | $33.18 | 2025 | Ohtuvayre |
| Blueprint Medicines Corporation | $26.36 | 2023 | Ayvakit |
| Gc Biopharma USA, INC. | $23.07 | 2024 | Alyglo |
| Octapharma USA, INC. | $21.11 | 2024 | Cutaquig |
| Phadia US INC. | $18.22 | 2021 | |
| Abbvie INC. | $15.93 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Laubach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.